Comparison 52. HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 52.1 Participant assessment of success by analysing scores and scales | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 52.1.1 4 weeks | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 52.1.2 8 weeks | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 52.1.3 16 weeks | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 52.2 Total adverse events | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected |